Liposomal Amphotericin B: 3 mg/kg

Liposomal Amphotericin B: 9 mg/kg

Voriconazole: 400 mg

Total

Sex: Female, Male

Region of Enrollment

Endpoint was whether participant had an invasive fungal infection or not, a potentially fatal complication with leukemia patients. Efficacy defined as absence of proven and probable fungal infection. Probable fungal infection is: 1) Positive radiographic findings consistent with fungal infections documented on CT imaging: Lower respiratory tract infection: halo sign, air crescent-sign, or cavity within areas of consolidation; Sinus: erosion of sinus walls or extension of infection to neighboring structures, extensive skull base destruction; and/or 2) Two positive galactomannan index test.

Number of Participants With Invasive Fungal Infection

Overall Study

Jorge Cortes, MD / Professor

Acute Myelogenous Leukemia

Myelodysplastic Syndrome

400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily

Voriconazole

3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes

Liposomal amphotericin B

9 mg/kg intravenously once per week over 2 hours +/- 15 minutes

The University of Texas M D Anderson Cancer Center

Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

Open, Randomized Comparative Trial of Two Different Schedules of Liposomal Amphotericin B Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

M.D. Anderson Cancer Center

blood samples, cells (fibroblasts) from skin biopsy tissue, DNA, urine and stool

sterol/lafyèv

Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency

Baz done ki pi konplè remèd fèy medsin te apiye nan syans